Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Pharma and TPG Pay $369 Million for Chindex

publication date: Feb 17, 2014
Fosun Pharma and private-equity company TPG have teamed up to take Chindex International private in a $369 million transaction. Chindex is a US company that owns and operates two private hospitals in China – one in Shanghai, the other in Beijing – plus multiple affiliated out-patient clinics. The deal reflects two prevalent China themes: the go-private trend among US-listed companies with China operations, and China’s new-found openness to foreign investment in healthcare delivery. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (NSDQ: CHDX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital